Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
7.21
0.00 (0.00%)
Nov 5, 2024, 11:14 AM EST - Market open
Aurinia Pharmaceuticals Employees
Aurinia Pharmaceuticals had 300 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
300
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$690,350
Profits / Employee
-$167,830
Market Cap
1.03B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
OPKO Health | 3,930 |
Phreesia | 1,438 |
MiMedx Group | 895 |
Arcutis Biotherapeutics | 296 |
Zymeworks | 278 |
Evolus | 273 |
Collegium Pharmaceutical | 197 |
89bio | 70 |
AUPH News
- 5 days ago - Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024 - Business Wire
- 25 days ago - Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024 - Business Wire
- 6 weeks ago - Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis - Business Wire
- 6 weeks ago - 3 Small Biotech Stocks With The 'Big Mo' Right Now - Seeking Alpha
- 6 weeks ago - Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment - Seeking Alpha
- 6 weeks ago - Aurinia Pharmaceuticals: This Recovery Can Continue - Seeking Alpha
- 7 weeks ago - Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference - Business Wire
- 7 weeks ago - Aurinia Announces Board Restructuring - Business Wire